Online Only Articles

Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

Departments of Cancer Evolution Research Center, The Catholic University of Korea, Seoul, South Korea;Precision Medicine Research Center, The Catholic University of Korea, Seoul, South Korea
Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Precision Medicine Research Center, The Catholic University of Korea, Seoul, South Korea
Integrated Research Center for Genome Polymorphism, The Catholic University of Korea, Seoul, South Korea
Integrated Research Center for Genome Polymorphism, The Catholic University of Korea, Seoul, South Korea
Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea;Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
Precision Medicine Research Center, The Catholic University of Korea, Seoul, South Korea;Integrated Research Center for Genome Polymorphism, The Catholic University of Korea, Seoul, South Korea;Microbiology, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Vol. 102 No. 11 (2017): November, 2017 https://doi.org/10.3324/haematol.2017.168070